Retatrutide, developed by Soma Pharmaceuticals , is attracting significant attention as a novel treatment for metabolic regulation. This dual-action drug merges the properties of a GLP-1 receptor agonist and a GIP receptor stimulant, designed to effectively promote weight loss but also improve related metabolic factors. Preliminary clinical tria… Read More